Seattle Genetics (NASDAQ:SGEN) Given New $188.00 Price Target at Needham & Company LLC

Share on StockTwits

Seattle Genetics (NASDAQ:SGEN) had its price target hoisted by Needham & Company LLC from $163.00 to $188.00 in a research report released on Tuesday morning, BenzingaRatingsTable reports. They currently have a buy rating on the biotechnology company’s stock.

A number of other equities research analysts have also recently issued reports on SGEN. ValuEngine cut shares of Seattle Genetics from a buy rating to a hold rating in a research report on Monday, May 4th. Barclays reiterated a hold rating on shares of Seattle Genetics in a research note on Sunday, May 3rd. HC Wainwright boosted their target price on Seattle Genetics from $150.00 to $175.00 and gave the stock a buy rating in a report on Friday, May 1st. JMP Securities began coverage on Seattle Genetics in a report on Tuesday, May 26th. They set an outperform rating and a $185.00 price target for the company. Finally, Royal Bank of Canada boosted their price objective on Seattle Genetics from $148.00 to $149.00 and gave the stock an outperform rating in a research note on Friday, May 1st. One research analyst has rated the stock with a sell rating, ten have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $147.42.

Shares of SGEN opened at $169.92 on Tuesday. The stock has a market cap of $28.45 billion, a PE ratio of -90.38 and a beta of 1.42. Seattle Genetics has a 1 year low of $63.02 and a 1 year high of $175.64. The stock has a 50 day simple moving average of $158.02 and a 200-day simple moving average of $127.98.

Seattle Genetics (NASDAQ:SGEN) last announced its quarterly earnings results on Thursday, April 30th. The biotechnology company reported ($0.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.17). The company had revenue of $234.51 million during the quarter, compared to the consensus estimate of $207.59 million. Seattle Genetics had a negative net margin of 32.81% and a negative return on equity of 16.51%. The business’s revenue was up 20.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.08) earnings per share. As a group, analysts anticipate that Seattle Genetics will post -2.8 earnings per share for the current fiscal year.

In other Seattle Genetics news, EVP Charles R. Romp sold 5,056 shares of the company’s stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $166.18, for a total value of $840,206.08. Following the completion of the sale, the executive vice president now owns 54,575 shares of the company’s stock, valued at $9,069,273.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Clay B. Siegall sold 28,472 shares of the stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $120.01, for a total transaction of $3,416,924.72. The disclosure for this sale can be found here. Insiders sold 700,756 shares of company stock worth $110,414,053 in the last three months. Insiders own 31.10% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Capital International Investors grew its stake in Seattle Genetics by 1.1% in the first quarter. Capital International Investors now owns 18,471,566 shares of the biotechnology company’s stock valued at $2,131,249,000 after acquiring an additional 209,264 shares during the period. BlackRock Inc. lifted its holdings in shares of Seattle Genetics by 12.2% during the 1st quarter. BlackRock Inc. now owns 11,039,007 shares of the biotechnology company’s stock valued at $1,273,681,000 after purchasing an additional 1,201,388 shares in the last quarter. Baillie Gifford & Co. grew its position in shares of Seattle Genetics by 0.6% in the 1st quarter. Baillie Gifford & Co. now owns 4,280,810 shares of the biotechnology company’s stock valued at $493,919,000 after purchasing an additional 24,181 shares during the period. State Street Corp increased its stake in Seattle Genetics by 3.8% during the 1st quarter. State Street Corp now owns 3,229,723 shares of the biotechnology company’s stock worth $372,645,000 after purchasing an additional 117,760 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Seattle Genetics by 6.0% during the 1st quarter. Geode Capital Management LLC now owns 1,465,893 shares of the biotechnology company’s stock worth $169,001,000 after purchasing an additional 83,052 shares in the last quarter. Hedge funds and other institutional investors own 94.33% of the company’s stock.

About Seattle Genetics

Seattle Genetics, Inc, a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas.

Featured Story: What is a price target?

Analyst Recommendations for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Nexus Investment Management ULC Decreases Position in Microsoft Co.
Nexus Investment Management ULC Decreases Position in Microsoft Co.
16,515 Shares in AT&T Inc.  Acquired by Cottage Street Advisors LLC
16,515 Shares in AT&T Inc. Acquired by Cottage Street Advisors LLC
Forte Capital LLC ADV Invests $488,000 in Intel Co.
Forte Capital LLC ADV Invests $488,000 in Intel Co.
16,081 Shares in Applied Materials, Inc.  Acquired by Mount Yale Investment Advisors LLC
16,081 Shares in Applied Materials, Inc. Acquired by Mount Yale Investment Advisors LLC
Diligent Investors LLC Buys New Stake in Marsh & McLennan Companies, Inc.
Diligent Investors LLC Buys New Stake in Marsh & McLennan Companies, Inc.
455 Shares in Netflix, Inc.  Acquired by Diligent Investors LLC
455 Shares in Netflix, Inc. Acquired by Diligent Investors LLC


 
© 2006-2020 Zolmax.